Drug Search Results
More Filters [+]

Ularitide

Alternative Names: ularitide, urodilatin
Latest Update: 2024-03-29
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: GUC Activator

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Cardiorentis
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ularitide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Heart Failure, Acute

Phase 2: Kidney Diseases|Acute Kidney Injury|Heart Failure, Acute|Hypertension, Pulmonary|Liver Cirrhosis

Phase 1: Heart Failure

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2020-004815-29

P2

Temporarily not available

Hypertension, Pulmonary

2023-08-04

ULA04

P2

Terminated

Liver Cirrhosis

2022-11-30

TRUST

P2

Terminated

Acute Kidney Injury

2022-09-26

2019-002268-28

P2

Terminated

Liver Cirrhosis

2022-01-13

Recent News Events